Should I buy or sell Concord Biotech?

The average broker rating on Concord Biotech is Buy. The breakup of analyst rating is given below - 1 analysts have given a strong sell rating 1 analysts have given a sell rating 1 analysts have given a hold rating 1 analysts have given a buy rating 2 analysts have given a strong buy rating

Is Concord Biotech a good stock to invest in?

Concord Biotech can be analyzed on the following key metrics - TTM P/E: 54.87 Sector P/E: 27.87 Dividend Yield: 0.38 D/E ratio: -

Gainers & Losers

Wed Jan 15 2025 10:21:59

NTPC share price
₹321.253.35%

Power Grid Corporation Of ...
₹298.803.03%

Kotak Mahindra Bank share price
₹1,789.302.29%

Maruti Suzuki India share price
₹11,940.601.69%

Tech Mahindra share price
₹1,673.901.62%

Active Stocks

Wed Jan 15 2025 10:29:49

Axis Bank share price
₹1,027.35-2.14%

Adani Power share price
₹549.301.88%

Tata Steel share price
₹126.55-0.35%

Bharat Electronics share price
₹268.00-0.70%

Tata Power share price
₹365.502.34%

Overview

Analysis

Concord Biotech Financials

Technical

Peers

Shareholding

Concord Biotech Corporate Actions

Company Profile

Concord Biotech share price

Sector: -

Concord Biotech is trading -3.35% lower at Rs 2,251.35 as compared to its last closing price. Concord Biotech has been trading in the price range of 2,355.00 & 2,215.05. Concord Biotech has given 5.28% in this year & 7.11% in the last 5 days.

Concord Biotech has TTM P/E ratio 54.87 as compared to the sector P/E of 27.87.There are 3 analysts who have initiated coverage on Concord Biotech. There are 1 analysts who have given it a strong buy rating & 1 analysts have given it a buy rating. 0 analysts have given the stock a sell rating.

The company posted a net profit of 95.74 Crores in its last quarter.

Listed peers of Concord Biotech include GO DIGIT GENERAL INSURANCE (-0.33%), Emcure Pharmaceuticals (0.48%), Concord Biotech (-3.35%) etc.

The Mutual Fund holding in Concord Biotech was at 4.97% in 30 Sep 2024. The MF holding has decreased from the last quarter. The FII holding in Concord Biotech was at 8.10% in 30 Sep 2024. The FII holding has increased from the last quarter.

2,251.35 -77.95 (-3.35%)Updated : Wed 15 Jan, 2025 | 15:48:59

Concord Biotech share price range

Today's Low

2,215.05

Today's High

2,355.00

52 Week Low

1,326.90

52 Week High

2,658.00

Concord Biotech share Key Metrics

Updated on 15 Jan 2025, 01:10 AM IST

Market Cap ( ₹ Cr.)

24,348.38

Beta	-
Div. Yield (%)	0.38
P/B	15.95
D/E	-
Open Price	2,330.00

TTM P/E	54.87
Peg. Ratio	6.64
Sector P/E	27.87
Prev. Close	2,329.30

CONCORDBIO share Key metrics

Concord Biotech stock Analysis

Price Analysis

1 Week	7.11%
3 Months	20.30%
6 Month	36.76%
YTD	5.28%
1 Year	66.66%

Risk Meter

47%High risk
47%High risk
47%High risk
47%High risk
47%High risk

Recos

Strong Sell
Sell
Hold
Buy
Strong Buy

Analysts' Views

Ratings	Current	1 W Ago	1 M Ago	3 M Ago
Strong Buy	1	1	1	1
Buy	1	1	1	0
Hold	1	1	1	1
Sell	0	0	0	1
Strong Sell	0	0	0	0
Total	3	3	3	3

Technical Trends

Long Term
Considers price movement over the last 6 months

Not Available

Short Term
Considers price movement over the last 1-2 weeks

Not Available

Bearish
Moderately Bearish
Neutral
Moderately Bullish
Bullish

Insight: Trends unavailable at the moment.

Concord Biotech Financials

INCOME
BALANCE SHEET
Cashflow

Annual

Quarterly

Period	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Total Revenue	1,016.94	853.17	712.93	616.94
Selling/ General/ Admin Expenses Total	243.19	225.17	199.13	132.42
Depreciation/ Amortization	53.59	54.03	50.05	27.52
Other Operating Expenses Total	7.94	4.97	4.50	3.34
Total Operating Expense	638.90	562.07	489.33	314.70
Operating Income	378.04	291.10	223.60	302.24
Net Income Before Taxes	412.56	322.01	237.52	312.72
Net Income	308.10	240.09	174.93	234.89
Diluted Normalized EPS	29.45	22.96	16.72	22.45

*All figures in crores except per share values

Detailed CONCORDBIO Financials

Concord Biotech forecast

Income Sheet (In Cr)Net Income Vs Revenue

Returns Metrics (In Cr)ROA Vs ROE

Mutual Fund Ownership

Ownership as on: Wed, 15 Jan, 2025

DSP Healthcare Fund Regular Growth

Equity

Amount Invested (Cr.)129.11

% of AUM3.87%

Baroda BNP Paribas Large and Mid Cap Fund Regular Growth

3/5

Equity

Amount Invested (Cr.)36.48

% of AUM2.37%

Invesco India Multicap Fund Growth

3/5

Equity

Amount Invested (Cr.)77.51

% of AUM1.95%

Invesco India Manufacturing Fund Regular Growth

Equity

Amount Invested (Cr.)15.98

% of AUM1.87%

Invesco India Aggressive Hybrid FundRegular Growth

3/5

Hybrid

Amount Invested (Cr.)9.32

% of AUM1.56%

View All

Concord Biotech Company profile

ABOUT Concord Biotech

Industry -
ISIN INE338H01029
BSE Code 543960
NSE Code CONCORDBIO

Concord Biotech Limited is an India-based research and development driven biopharma company. The Company is engaged in the research and development, manufacturing, marketing, and selling of pharmaceutical products. The Company manufactures active pharmaceutical ingredients (API) through fermentation and semi-synthetic process and finished formulations. The Company’s offerings span both bio-pharmaceutical APIs and formulations across therapeutic areas like immunosuppressants oncology, anti-infectives nephrology, and critical care. Its portfolio also includes fermentation-based APIs in anti-bacterial, anti-fungal, and other therapeutic segments. Its API products include Mycophenolate Mofetil, Mycophenolate Sodium, Cyclosporine, Sirolimus, Pimecrolimus, Voclosporin, Mupirocin, Mupirocin Calcium, Vancomycin Hydrochloride, Teicoplanin, Polymyxin B Sulfate, Fidaxomicin, Anidulafungin. Its API products under development include Daptomycin, Epirubicin, Idarubicin, and Pirarubicin.

Concord Biotech Management

Sudhir Vaid Executive Chairman of the Board, Managing Director
Ankur Vaid Chief Executive Officer, Joint Managing Director, Executive Director
Lalit Sethi Chief Financial Officer
Prakash Sajnani Compliance Officer, Company Secretary, Assistant Vice President - Finance
Devang Bhatt Vice President - Sales and Marketing, Head - Limbasi Plant - 3
Manoj Kumar Vice-President - Formulation Division and Head - Valthera Unit - 2
Sundeep Bengani General Manager - International Business Development, Formulation Division

FAQs about Concord Biotech share price

Concord Biotech is trading at 2251.35 as on Wed Jan 15 2025 10:18:59. This is -3.35% lower as compared to its previous closing price of 2329.30.

The market capitalization of Concord Biotech is 24348.38 Cr as on Wed Jan 15 2025 10:18:59.

The average broker rating on Concord Biotech is Buy. The breakup of analyst rating is given below -

1 analysts have given a strong buy rating
1 analysts have given a buy rating
1 analysts have given a hold rating
0 analysts have given a sell rating
0 analysts have given a strong sell rating

The 52 wk high for Concord Biotech is 2658.00 whereas the 52 wk low is 1326.90

Concord Biotech can be analyzed on the following key metrics -

TTM P/E: 54.87
Sector P/E: 27.87
Dividend Yield: 0.38%
D/E ratio: -

Concord Biotech reported a net profit of 308.10 Cr in 2024.

Trending Stocks

NTPC share price

321.25+10.40(3.35%)

Power Grid Corporation Of India share price

298.80+8.80(3.03%)

Kotak Mahindra Bank share price

1,789.30+40.05(2.29%)

Mahindra & Mahindra share price

2,960.05-88.60 (-2.91%)

Bajaj Finserv share price

1,673.45-38.80 (-2.27%)

Home Markets Premium Instant Loan Mint Shorts

Meeting Date	Purpose
11-Nov-24	Quarterly Results
09-Aug-24	Quarterly Results
23-May-24	Audited Results & Dividend
08-Feb-24	Quarterly Results
08-Nov-23	Quarterly Results

Meeting Date	Announcement On	Purpose
29-Jun-24	14-Jun-24	AGM

Announcement On	Record Date	Ex-Dividend	Dividend Value
23-May-24	22-Jun-24	21-Jun-24	8.75

Concord Biotech share price

Concord Biotech share price range

Concord Biotech share Key Metrics

Concord Biotech stock Analysis

Technical Trends

Long Term
Considers price movement over the last 6 months

Short Term
Considers price movement over the last 1-2 weeks

Concord Biotech share price news

Breakout stocks to buy or sell: Sumeet Bagadia recommends five shares to buy today — Dec 12

Breakout stocks to buy or sell: Reliance Infra to Prism Johnson — Sumeet Bagadia recommends five shares to buy today

Concord Biotech share price surges 20%; Kotak upgrades the stock to an add; here's what the brokerage firm says

Stocks to watch: Timken, LIC, NMDC, Inox Wind, Hudco, Dish TV, Goodyear

13 IPOs listed in FY24 deliver multibagger returns in the range of 104%-325%; did you invest?

Concord Biotech Financials

Concord Biotech forecast

Concord Biotech Technical

Concord Biotech Shareholding

Shareholding Pattern

DSP Healthcare Fund Regular Growth

Baroda BNP Paribas Large and Mid Cap Fund Regular Growth

Invesco India Multicap Fund Growth

Invesco India Manufacturing Fund Regular Growth

Invesco India Aggressive Hybrid FundRegular Growth

Concord Biotech Corporate actions

Concord Biotech Company profile

ABOUT Concord Biotech

Concord Biotech Management

FAQs about Concord Biotech share price

Concord Biotech Quick Links

Equity Quick Links

Concord Biotech share price

Concord Biotech share price range

Concord Biotech share Key Metrics

Concord Biotech stock Analysis

Long TermConsiders price movement over the last 6 months

Short TermConsiders price movement over the last 1-2 weeks

Concord Biotech Financials

Concord Biotech forecast

Concord Biotech Technical

Concord Biotech Shareholding

Shareholding Pattern

Concord Biotech Corporate actions

Concord Biotech Company profile

ABOUT Concord Biotech

Concord Biotech Management

FAQs about Concord Biotech share price

Concord Biotech Quick Links

Equity Quick Links

Wait for it…

Wait for it…

Long Term
Considers price movement over the last 6 months

Short Term
Considers price movement over the last 1-2 weeks